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Abstract
Previous studies identified two mammalian prion protein (PrP) polybasic domains that bind the disease-associated
conformer PrP
Sc, suggesting that these domains of cellular prion protein (PrP
C) serve as docking sites for PrP
Sc during prion
propagation. To examine the role of polybasic domains in the context of full-length PrP
C, we used prion proteins lacking
one or both polybasic domains expressed from Chinese hamster ovary (CHO) cells as substrates in serial protein misfolding
cyclic amplification (sPMCA) reactions. After ,5 rounds of sPMCA, PrP
Sc molecules lacking the central polybasic domain (DC)
were formed. Surprisingly, in contrast to wild-type prions, DC-PrP
Sc prions could bind to and induce quantitative conversion
of all the polybasic domain mutant substrates into PrP
Sc molecules. Remarkably, DC-PrP
Sc and other polybasic domain PrP
Sc
molecules displayed diminished or absent biological infectivity relative to wild-type PrP
Sc, despite their ability to seed
sPMCA reactions of normal mouse brain homogenate. Thus, DC-PrP
Sc prions interact with PrP
C molecules through a novel
interaction mechanism, yielding an expanded substrate range and highly efficient PrP
Sc propagation. Furthermore,
polybasic domain deficient PrP
Sc molecules provide the first example of dissociation between normal brain homogenate
sPMCA seeding ability from biological prion infectivity. These results suggest that the propagation of PrP
Sc molecules may
not depend on a single stereotypic mechanism, but that normal PrP
C/PrP
Sc interaction through polybasic domains may be
required to generate prion infectivity.
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Introduction
Prions are infectious proteinaceous particles that cause fatal
neurodegenerative diseases, including Creutzfeldt-Jakob disease
(CJD), bovine spongiform encephalopathy (BSE), and chronic
wasting disease (CWD). Prions contain PrP
Sc, a protease-resistant
detergent-insoluble b-sheet-rich conformer of the normal cellular
protein PrP
C [1,2]. PrP
Sc is an essential and possibly the sole
component of infectious prions. Prion propagation and disease
require the presence of PrP
C, encoded by the host Prnp gene
[3,4,5,6].
Cell-free in vitro propagation systems have emerged as valuable
tools to investigate PrP
Sc and prion propagation [7]. By serial
protein misfolding cyclic amplification (sPMCA), prion infectivity
can be propagated in vitro [8]. More rapid and less costly than the
gold standard inoculation bioassay, sPMCA has been proposed as
an in vitro method to detect prion infectivity [9]. Indeed, samples
which seed robust sPMCA propagation have been previously
associated with biological infectivity [8,10]. However, it is
unknown if PrP
Sc molecules that robustly seed PMCA propagation
in wild type brain homogenate are always associated with
appropriate levels of specific infectivity.
Recent studies have reconstituted infectious PrP
Sc propagation
using purified PrP
C substrate and supplementary conversion
cofactors, a set of minimal components that appear necessary for
prion propagation [11,12]. PrP
Sc appears to propagate by
autocatalysis, binding PrP
C to induce conversion into a new PrP
Sc
molecule [13]. However, the mechanisms of binding and
conversion remain unclear.
Studies using motif-grafted antibodies or PrP-derived peptides
identified two polybasic regions that bind strongly to PrP
Sc
[14,15,16], suggesting that these PrP
C domains may serve as
docking sites for PrP
Sc. The N-terminal (N-PBD, 23–28) and
central (C-PBD, 100–109) polybasic domains both fall in the N-
terminal flexible region of PrP
C, which is less ordered than the C-
terminus [17,18]. Antibodies directed at C-PBD can impede prion
propagation in cultured cells and in vivo [19,20], possibly by
blocking a PrP
Sc-binding site on PrP
C. The polybasic domains
may also be involved in interaction with lipid molecules during the
conversion process [21] and may affect the structure of misfolded
prion protein [22].
Mice overexpressing PrP transgenes lacking amino acids 23–88
show reduced prion susceptibility [23], but these studies did not
examine N-PBD in isolation. Transgenic mice with deletions that
include C-PBD display lethal neurologic illness, but this phenotype
precluded inoculation experiments assessing prion susceptibility
[24,25,26]. The specific role of these domains in the context of the
entire PrP
C molecule has been studied in N2a cells co-expressing
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C [27], but biochemical examinations of
binding interactions and of propagation with pure substrates are
lacking.
In full-length PrP
C, the relative importance of the N-terminal
and central polybasic domains in binding PrP
Sc is unclear.
Moreover, while much evidence points to a significant role for
PrP
C polybasic domains, it is not known if PrP
Sc-PrP
C interactions
are universally stereotypic – whether all PrP
Sc molecules use the
same PrP
C epitopes for interaction.
Using a combination of Chinese hamster ovary (CHO) cell
expression, protein purification, and reconstitution sPMCA
techniques, we engineered PrP
Sc molecules lacking polybasic
domains. These novel PrP
Sc molecules, which propagate robustly
in vitro, enabled us to assess whether PrP
C polybasic domains are
universally required for PrP
Sc docking and propagation. PBD-
deficient PrP
Sc molecules also provided us with a unique
opportunity to dissect the relationship between the ability to seed
formation of wild type PrP
Sc molecules in vitro and prion infectivity
in vivo.
Materials and Methods
Mutagenesis and expression of recPrP-myc for binding
Sequence encoding mouse PrP-A 23–230 was amplified, using
the following primers to add an N-terminal start codon and a C-
terminal tag encoding amino acids 410–419 of human c-myc
(NCBI accession number NP_002458.2): N: 59- aaaaaacatatgaa-
aaagcggccaaagcctggagggt-39,C :5 9-aaaactcgagtcattacagatcctcttctg-
agatgagtttttgttcggatcttctcccgtcgtaatag-39. This fusion gene was
inserted into pET22b(+) for bacterial expression. N-terminal
(DN, 23–28) and central (DC, 100–109) polybasic domains were
deleted by site-directed mutagenesis (GeneTailor, Invitrogen,
Carlsbad, CA). From transfected Escherichia coli Rosetta cells,
recombinant PrP was purified in a manner similar to that
described by Wang et al. [12]. Cells from 500 mL induced
(Overnight Express Autoinduction System, Novagen, EMD
Chemicals, Gibbstown, NJ) overnight culture were pelleted at
8,0006g for 10 min.; lysed with 40 mL BugBuster, Lysonase
(Novagen), and intermittent sonication over 20 min.; and inclusion
bodies were prepared by two cycles of centrifugation (16,0006g,
15 min.) and 0.16 Bugbuster resuspension, followed by an
additional 16,0006g 15 min. spin. Inclusion body pellets were
solubilized in 8 mL 8 M guanidine hydrochloride, insoluble
material removed by centrifugation (8,0006g, 10 min.), and
protein added to 3.6 g Ni-NTA Hisbind Superflow resin
(Novagen) pre-equilibrated in denaturing buffer (100 mM sodium
phosphate, 10 mM Tris, 6 M Guanidine, 10 mM b-mercapto-
ethanol, pH 8.0). After 30 min. binding, resin was transferred to
column support, and protein was refolded by a linear 12 hr.
125 mL gradient of denaturing to refolding buffer (100 mM
sodium phosphate, 10 mM Tris, pH 8.0), followed by 60 mL wash
at 1 mL/min. in refolding buffer. Protein was eluted from nickel
affinity resin by 1 mL/min. 500 mM imidazole, 100 mM sodium
phosphate pH 6.5; then dialyzed into 20 mM sodium phosphate
pH 6.5 (362 L for 30 min.) and into water (362 L for 30 min.,
164 L overnight). If observed, precipitate was removed by
centrifugation at 100,0006g for 60 min. The nickel eluate was
loaded on 2 mL pre-equilibrated (30 mL 10 mM sodium
phosphate pH 6.5, 1 mL/min.) CM sepharose (Sigma, St. Louis,
MO) at 0.5 mL/min., washed with 50 mL NaCl at 1 mL/min.,
and eluted with a gradient (300–650 mM NaCl, 0.5 mL/min.).
Fractions containing .0.1 OD280 (.0.037 mg/mL PrP) [28] were
pooled and dialyzed into water (264 L for 30 min., 164L
overnight), then stored at 270uC. Protein concentration was
determined by bicinchoninic acid (BCA) assay.
PrP
Sc-PrP binding assays
RML scrapie-infected brain homogenate (5% BH in tris-
buffered saline) or CHO DC-PrP
Sc (sPMCA round 16 product,
therefore 10
16-fold dilution of original wild-type scrapie seed) were
vortexed for 15 sec., sonicated for 1 min. at 70% power (Misonix
4000 with Microplate Horn, Qsonica, Newtown, CT), and
centrifuged at 5006g for 15 min. Normalized amounts of this
clarified preparation (12.4 mL brain homogenate PrP
Sc, 16.5 mL
PrP
Sc) were incubated with 3.5 mg purified E. coli recPrP-myc
(wild-type or lacking polybasic domain) in 250 mL binding buffer
(50 mM tris, 200 mM NaCl, 1% Triton X-100, 1% Tween-20,
pH 7.5) for 1 hr. at 4uC with 10 r.p.m. end-over-end rotation.
Concurrently, 16 mL 30 mg/mL Dynabeads Protein A (Invitro-
gen) was washed with 26500 mL phosphate-buffered saline (PBS),
collected by a Magnetic Particle Separator (PureBiotech, Mid-
dlesex, NJ), and incubated with 3.6 mg 9E10 anti-myc antibody
(Santa Cruz Biotechnology, Santa Cruz, CA) in 250 mL binding
buffer for 30 min. at room temp. with 10 r.p.m. end-over-end
rotation. Next, the solution of PrP
Sc and PrP-myc was added to the
bead-anti-myc complexes, and rotated for 1 hr. at 4uC. Following
this incubation, beads were collected, and supernatant was
aspirated. Beads were rinsed in 46500 mL wash buffer (50 mM
tris, 200 mM NaCl, 0.05% Tween 20), and analyzed for bound
PrP
Sc. Signal intensities were quantified by densitometry with
ImageGauge V4.22 (Fujifilm) in quant mode.
Expression and preparation of PrP from Chinese hamster
ovary (CHO) cells
Sequences encoding wild-type and polybasic domain deletion
mutant (DN=D23–28; DC-PBD=D100–109; DD-PBD=D23–28
D100–109) PrP were inserted in pcDNA5/FRT plasmids. These
were used to express PrP from CHO cells, which was prepared as
described previously [29]. For hamster experiments, homologous
deletion mutants were used (D23–28, D101–110, or DD).
Reconstituted serial protein misfolding cyclic
amplification (sPMCA) with CHO-expressed PrP
Reactions were prepared and carried out as described by
Geoghegan et al. [29]. Briefly, CHO-expressed mouse PrP (wild-
type or polybasic domain deletion mutant) was mixed with Prnp
0/0
Author Summary
Prions are unconventional infectious agents that cause
fatal diseases in humans and other animals. Previous
studies have suggested that prion infectivity depends
upon the ability of a sample to change the shape of a
normal brain protein called the prion protein (PrP) into a
disease-associated shape. Other studies have identified a
pair of positively charged domains within the structure of
PrP that appear to be important for the interaction
between the normal and disease-associated shapes of
the prion protein. In this report, we show that the shape of
normal PrP can change into the disease-associated form
through a novel mechanism that does not involve
positively charged domains. However, it appears that
interaction through the positively charged domains is
required to produce infectious prions efficiently. Our
results show for the first time that the ability to change
the shape of normal PrP into its disease-associated state is
not the sole determinant of prion infectivity.
Alternate Prion Mechanism
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microliters of this reconstituted substrate was mixed with 10 mL
seed. Reactions were initially seeded with 0.1% scrapie-infected
brain homogenate (mouse strain RML) in PBS, with 10 mLo f
product used to seed the subsequent round. DC-PrP
Sc seed was
produced by 16 rounds of sPMCA (10
16-fold dilution of original
wild-type scrapie seed), containing ,1 original PrP
Sc molecule [8].
Unseeded reactions were given 10 mL PBS as initial seed. For
reactions lacking cofactor, buffer (PBS 1% Triton X-100) replaced
Prnp
0/0 brain homogenate. Each PMCA round consisted of
incubation at 37uC for 24 hr. with 20 sec. microplate horn
sonication at 85% power every 30 min. One set of seeded samples
was not subjected to PMCA (round 0), while another set was not
subjected to protease digestion (2PK) to observe input PrP. For
hamster sPMCA experiments, or Sc237 strain was used, CHO
HaPrP was supplemented with 20 mg/mL synthetic poly(A) RNA
(Sigma, St. Louis, MO), and PrP
Sc was detected by immunoblot
after 50 mg/mL digestion for 60 min.
sPMCA with brain homogenate
Brain homogenate sPMCA experiments were adapted from
Castilla et al. [30]. 90 mL 10% CD-1 mouse brain (Biochemed,
Winchester, VA) homogenate was prepared in PBS, 1% Triton X-
100, 5 mM EDTA, Roche Complete mini protease inhibitor, then
seeded with PrP
Sc (10 mL of round 16 product). One round of
PMCA consisted of 30 sec. 90% power microplate horn sonication
pulses every 30 min. for 24 hr. at 37uC. 10 mL of each reaction
product was transferred to fresh brain homogenate for the
following round.
PrP
Sc detection
Mouse PrP
Sc was detected by digestion with 25 mg/mL
proteinase K (Roche, Indianapolis, IN) for 30 min. at 37uC and
750 r.p.m. shaking, polyacrylamide gel electrophoresis (PAGE),
transfer to polyvinylidene fluoride (PVDF), and Western detection
with anti-PrP and horseradish peroxidase-conjugated anti-mouse
sheep IgG (GE Healthcare, Piscataway, NJ). Signals were detected
by enhanced chemiluminescence (ECL) (SuperSignal West Femto
Substrate, Pierce, Rockford, IL) and visualized by a Fuji (Fujifilm)
LAS-3000 chemiluminescence documentation system. Hamster
PrP
Sc was detected with 50 mg/mL proteinase K for 60 min.
Experiments detecting only wild-type PrP used 6D11 anti-PrP
antibody. Because the central polybasic domain (C-PBD) forms
part of the 6D11 epitope, and therefore DC PrP is not detected by
6D11 (data not shown), reconstituted sPMCA experiments utilized
anti-PrP mAb 27/33.
Biological infectivity assay
RML PrP
Sc, propagated with CHO wild-type or DC- PrP
C in
vitro by sPMCA (Figures 1B, S4) for at least 14 rounds, was diluted
1:10 in diluent (PBS+1 mg/mL BSA). DN- and DD-PrP
Sc
molecules, propagated from DC-PrP
Sc (Figure 2B), were prepared
in the same manner. By serial dilution, each inoculum contained
10
215 of the original seed, equivalent to less than one original
PrP
Sc molecule [8]. PrP
Sc preparations (30 mL) were injected
intracerebrally into female CD-1 mice aged 6 weeks (Charles
River Laboratories, Wilmington, MA). For two samples (DC-PrP
Sc
and DD-PrP
Sc), end-point dilution bioassays were performed, in
which 10-fold serial dilutions were inoculated to measure the
amount of prion infectivity present in the original sample. As
described previously [11], animals were monitored daily for
clinical signs of neurological dysfunction over the standard one-
year observation period. Animals showing terminal scrapie were
sacrificed, and their brains were analyzed for PrP
Sc (by 25 mg/mL
protease digestion and immunoblot) and for spongiform degener-
ation (by hematoxylin & eosin histology) [11]. Random asymp-
tomatic animals were sacrificed after one year, and their brains
were likewise analyzed for PrP
Sc and spongiform degeneration.
Ethics statement
All animals were handled in strict accordance with good animal
practice, as defined by the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
Dartmouth College Institutional Animal Care and Use Committee
approved the animal work (assurance number A3259-01).
Inoculations were performed under isoflurane anesthesia, and all
efforts were made to minimize suffering.
Results
Interaction and propagation of wild-type PrP
Sc with PrP
molecules lacking polybasic domains
Studies using fragments of PrP identified N-terminal (23–28)
and central (100–109 in mouse) polybasic domains as potential
binding sites for PrP
Sc [14,16]. To investigate the role of these
domains in the context of full-length PrP
C, we developed a novel
magnet-based assay to examine direct interaction between PrP
Sc
and PrP
C molecules with or without deletions of these polybasic
regions. In this assay, PrP
Sc was incubated with purified
recombinant myc-tagged PrP, and then adherent molecules were
pulled down by a-myc antibodies attached to Protein A magnetic
beads. Substitution of a short myc epitope in place of the C-
terminal glycophosphatidylinositol anchor of PrP
C permitted
specific capture. The assay specifically assesses PrP
Sc binding to
PrP (Figure S1 in Supporting Information S1), and indicates that
purified PrP
Sc binds to purified PrP (Figure S2 in Supporting
Information S1). Next, we compared binding of PrP
Sc to wild-type
and mutant PrP substrates. In contrast to quantitative RML PrP
Sc
binding by wild-type PrP (,100% by densitometry), PrP lacking
the central polybasic domain (DC) bound significantly less PrP
Sc
(,50%) and N-terminal polybasic deletion mutant PrP (DN)
bound still less PrP
Sc (,20%) (Figure 1A). Purified PrP
Sc also
adhered to wild-type PrP more strongly than to polybasic mutant
PrP (Figure S2 in Supporting Information S1). These results
suggest that both PrP polybasic domains contribute to PrP
Sc
binding.
To test the function of PrP
C polybasic domains in prion
propagation, we performed sPMCA experiments with wild type
and mutant PrP
C substrate. These PrP
C molecules, prepared from
CHO cells transfected with wild-type or mutant Prnp DNA, were
detergent-soluble (Figure S3 in Supporting Information S1) and
membrane-anchored (Figure S4 in Supporting Information S1),
indicative of proper folding and intracellular trafficking. In
reconstituted, three-round sPMCA experiments with PrP
C and
Prnp
0/0 brain homogenate, PrP
Sc propagated efficiently, convert-
ing the PrP
C to protease-resistant autocatalytic PrP
Sc molecules
(Figure 1B and S5 in Supporting Information S1). In contrast,
PrP
C molecules missing one (DN, DC) or both (DD) polybasic
domains did not support efficient propagation, indicating that
PrP
C requires these domains to facilitate PrP
Sc propagation. This
result was also found with Sc237 hamster prions, as we observed
no propagation of protease-resistant PrP with polybasic mutant
hamster PrP
C (Figure S5 in Supporting Information S1).
When we examined propagation in polybasic mutant substrates
beyond three rounds, surprisingly, one mutant (DC) reproducibly
produced PrP
Sc molecules, typically between rounds 3–5
(Figure 1B). Further, these DC-PrP
Sc molecules propagated
robustly and indefinitely (Figure S6 in Supporting Information
Alternate Prion Mechanism
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C to support propagation despite
absence of the central polybasic domain. Indeed, DC-PrP
conversion was extremely efficient, with ,100% of substrate
converted to PrP
Sc, outpacing even wild-type PrP conversion
ratios (,20% of substrate). DC-PrP
Sc molecules appear to derive
from the original wild-type PrP
Sc seed, as unseeded reactions did
not generate PrP
Sc (Figure 1B).
Interaction range of DC-PrP
Sc molecules
The unexpected generation of DC-PrP
Sc molecules led us to
conduct a series of experiments to assess the role of polybasic
domains in DC-PrP
Sc propagation. Using the magnetic myc-capture
assay,wetestedbindingtovariousPrPsubstrates.Incontrasttowild-
type PrP
Sc, DC-PrP
Sc reproducibly bound more strongly to DC-PrP
(,50% of input) than to wild type PrP (,35% of input) (Figure 2A).
Figure 1. Interaction of wild-type PrP
Sc with mutant PrP molecules. (A)B i n d i n go fP r P
Sc to PrP. RML scrapie-infected mouse brain
homogenate was incubated with myc-tagged PrP of wild-type sequence or lacking the central (DC-PBD: D100–109) or N-terminal (DN-PBD:
D23–28) polybasic domain. Bound PrP
Sc was captured with 9E10 anti-myc antibody on magnetic protein A Dynabeads, and detected by
25 mg/mL proteinase K digestion and anti-PrP (6D11) immunoblot. (B) Propagation of PrP
Sc. RML scrapie-infected mouse brain homogenate
was propagated by serial protein misfolding cyclic amplification (sPMCA) for five rounds with wild-type or polybasic deletion mutant PrP
C
prepared from Chinese hamster ovary (CHO) cells. Reactions were supplemented with Prnp
0/0 mouse brain homogenate. In addition to
scrapie-seeded reactions, an unseeded reaction was performed with DC-PBD PrP substrate. One sample of each reaction was not subjected to
protease digestion (2PK). All others were subjected to limited proteolysis with 25 mg/mL proteinase K. PrP was detected by immunoblot
(anti-PrP 27/33).
doi:10.1371/journal.ppat.1002128.g001
Alternate Prion Mechanism
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Sc bound to DN-PrP (,30% of input),
suggesting a significantly different interaction mechanism than
wild-type PrP
Sc. Interestingly, wild-type PrP
Sc-PrP
C binding ap-
peared stronger than DC-PBD mutant PrP
Sc-PrP
C interactions.
We next examined DC-PrP
Sc propagation with other polybasic
mutant substrates. Fitting with its binding behavior, DC-PrP
Sc
propagated successfully in DN-PrP
C (Figure 2B). Moreover, the
DC-PrP
Sc seed also propagated in DD-PrP
C with robust conver-
sion, indicating that presence of a polybasic domain is not an
absolute requirement for PrP
C to convert to a protease-resistant
autocatalytic form. Indeed, all three types of DPBD-PrP
Sc
molecules propagated robustly, with stringent proteinase K
digestion (25 mg/mL) revealing a protease-resistant core with a
,7 kDa molecular weight shift.
Cofactor dependence and seeding specificity of PrP
Sc
molecules lacking polybasic domains
Infectious wild-type PrP
Sc molecules depend on accessory
cofactor molecules for propagation [11,12,31]. We tested whether
polybasic domain mutant PrP
Sc molecules exhibit this character-
istic by performing parallel sPMCA reactions, omitting the
supplemental Prnp
0/0 brain homogenate from one set (Figure 3).
All three PrP
Sc mutants (DC, DN, and DD) failed to propagate in
the absence of Prnp
0/0 brain homogenate, pointing to a cofactor-
dependent propagation mechanism. The signals seen in initial
rounds of cofactor-negative propagation are likely due to the
presence of residual Prnp
0/0 brain homogenate carried over from
the PrP
Sc seed mixture. By the third round of sPMCA in cofactor-
free substrate, no PrP
Sc molecules were detected.
Figure 2. Interaction of DC-PBD PrP
Sc with mutant PrP molecules. (A) Binding of DC-PBD PrP
Sc to PrP. DC-PBD PrP
Sc was incubated with wild-
type or polybasic mutant (DC-PBD, DN-PBD) myc-tagged PrP. Bound PrP
Sc was captured with 9E10 anti-myc antibody on magnetic protein A
Dynabeads, and detected by 25 mg/mL proteinase K digestion and anti-PrP (27/33) immunoblot. (B) Propagation of DC-PBD PrP
Sc. DC-PBD PrP
Sc was
propagated by sPMCA with polybasic deletion mutant PrP
C prepared from Chinese hamster ovary (CHO) cells. Reactions were supplemented with
Prnp
0/0 mouse brain homogenate. One sample of each reaction was not subjected to protease digestion (2PK), loading J of volume. All others were
subjected to limited proteolysis by 25 mg/mL proteinase K digestion. PrP was detected by immunoblot (anti-PrP 27/33).
doi:10.1371/journal.ppat.1002128.g002
Alternate Prion Mechanism
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Sc seeds propagation in wild-type brain homog-
enate [32,33] to the extent that successful sPMCA propagation is
considered potentially diagnostic for prion infectivity [9]. We
tested if DPBD-PrP
Sc molecules could seed propagation in wild-
type brain homogenate (Figure 4). Like wild-type PrP
Sc, all three
PrP
Sc polybasic mutants (DC, DN, and DD) seeded serial
propagation with success. Each of these reactions displayed
positive conversion signals in round 1, suggesting a high amount
of prion infectivity [34]. Interestingly, the PrP
Sc molecules that
formed were predominantly diglycosylated, whereas PrP
Sc mole-
cules formed from wild-type seeds displayed the three glycoforms
in equivalent amounts. It has been shown that the ability to
produce different PrPSc glycoforms is not due to preferential
interaction, but rather inherent conformation [35]. This study
found that mouse RML prions only require unglycosylated PrP
C
for propagation, and that glycosylated forms of PrP
Sc can be made
in its presence. This suggests that the observed glycosylation
pattern described here may be caused by a different fold in
polybasic mutant PrP
Sc.
Thus, all three PBD mutant PrP
Sc molecules share the hallmark
biochemical characteristics of infectious wild-type PrP
Sc molecules
[11]: (1) a highly protease-resistant core, (2) cofactor-dependent
propagation, and (3) the ability to seed wild-type brain
homogenate sPMCA reactions.
Infectivity of polybasic mutant PrP
Sc molecules
We tested whether mutant PrP
Sc molecules, generated in vitro
from CHO-expressed PrP, are infectious to animals. Following
sPMCA propagation sufficient to dilute out original seeds, wild-
type and mutant (DC, DN, and DD) PrP
Sc molecules were
inoculated intracerebrally into wild-type mice. Wild-type CHO
PrP
Sc contains significant infectivity, causing scrapie disease in all
animals with an incubation period comparable to RML prions
propagated in vitro in brain homogenate [36] (Table 1). Affected
animals displayed accumulation of protease-resistant prion protein
and significant histopathological spongiform degeneration
(Figure 5), as we previously reported for hamster prions
propagated in vitro in wild-type CHO-expressed hamster PrP
[29]. Animals inoculated with wild-type CHO PrP
Sc also showed
robust levels of protease-resistant PrP
Sc on Western blot.
In contrast to wild-type, polybasic mutant PrP
Sc molecules show
diminished in vivo infectivity. DC-PrP
Sc caused scrapie disease only
in a fraction of animals, including those receiving the most
concentrated inocula, with an incubation time 2.5-fold greater
than animals inoculated with wild-type PrP
Sc. DC-PrP
Sc-inoculat-
ed diseased animals showed mild vacuolation (Figures 5B and S7
in Supporting Information S1) and displayed low levels of PrP
Sc on
Western blot, with diglycosylated molecules most abundant. Such
a glycoform ratio contrasts with the even distribution of glycoforms
in animals inoculated with wild-type PrP
Sc (Figures 5A and S8 in
Supporting Information S1), also seen with in vitro propagation
(Figure 4). Both wild-type and DC-PrP
Sc induced scrapie illness
characterized neurologically by lethargy and ataxia. DN-PrP
Sc
molecules induced scrapie illness in a single animal, following a
564-day incubation period (Figure S9 in Supporting Information
S1), with other such inoculated animals showing no scrapie illness
(Figure 5). Due to the sudden nature of some deaths, we did not
obtain tissue from all animals, but brain samples from many non-
scrapie deaths were obtained as indicated in Table 1. DD-PrP
Sc
molecules did not induce scrapie illness, as gauged by clinical
observation and lack of protease-resistant PrP or histopathological
change in animals sacrificed over one year after inoculation
(Figure 5). Thus, while polybasic deletion mutant PrP
Sc molecules
recapitulated in vitro many characteristics of infectious PrP
Sc
molecules, they displayed low specific infectivity in wild-type mice.
Discussion
In this study, we have engineered polybasic domain deficient
PrP
Sc molecules that efficiently interact with and catalyze the
conversion of an expanded range of PrP
C substrates, including
native PrP
C in wild-type mouse brain homogenate. Remarkably,
despite possessing the biochemical characteristics and in vitro
Figure 3. Effect of accessory cofactors on the propagation of DPBD PrP
Sc molecules. In vitro-generated DC-PBD, DN-PBD, and DD-PBD
PrP
Sc molecules were propagated by sPMCA with autologous PrP
C prepared from Chinese hamster ovary (CHO) cells. One set of reactions was
supplemented with Prnp
0/0 mouse brain homogenate (+cofactor), while a second set received only buffer (2cofactor). One sample of each reaction
was not subjected to protease digestion (2PK), while all others were digested with 25 mg/mL proteinase K. –PK reactions for DC-PBD and DD-PBD
were loaded with J volume. PrP was detected by immunoblot (anti-PrP 27/33).
doi:10.1371/journal.ppat.1002128.g003
Alternate Prion Mechanism
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Sc molecules
possessed little or no in vivo infectivity.
Requirement of PrP
C polybasic domains for propagation
of wild-type PrP
Sc
Studies of PrP fragments have indicated that polybasic
domains can interact with PrP
Sc [14,16]. To investigate both
prion binding and conversion in the context of the entire PrP
molecule, we designed mutant prion proteins lacking one or both
polybasic domains, which were detergent-soluble and properly
trafficked, as determined by PI-PLC release. Using a novel
magnetic capture assay, we found that both PrP
C polybasic
domains were required for optimal PrP
Sc binding. In reconsti-
tuted sPMCA experiments with PrP expressed and prepared from
CHO cells, deletion of either or both polybasic domains of
substrate PrP
C prevented efficient propagation of wild-type PrP
Sc.
As mutants lacking either domain did not efficiently bind or
propagate wild-type PrP
Sc,b o t hP r P
C polybasic domains appear
required to contact PrP
Sc for efficient propagation of wild-type
prions.
Work using N2a cells co-expressing wild-type and mutant PrP
suggested that the N-terminal polybasic domain may not play a role
in conversion [27]. However, the presence of endogenous wild-type
PrP
C may have provided conditions that facilitated conversion of
the weaker-binding mutant PrP substrate. The results presented in
this paper, using mutant substrate alone to test binding and
propagation, suggest that the PrP
C N-terminal polybasic domain
indeed participates in wild-type PrP
Sc binding and propagation.
Delayed conversion of PrP lacking polybasic domains
When sPMCA reactions seeded with wild-type prions were
carried out to 3–5 rounds, DC-PrP
C substrate molecules converted
to a form resistant to protease digestion under stringent conditions
(25 mg/mL proteinase K at 37uC). After protease digestion, this
form displayed a classical shift in molecular weight of ,7 kDa. This
form was also autocatalytic, continuing to propagate robustly
(,100% conversion) and indefinitely in DC-PrP
C substrate. In
seeking to understand the surprising kinetics of the initialconversion
event, which occurred after four rounds and 10
24 dilution of the
original seed, we found that unseeded control reactions did not
Figure 4. DPBD PrP
Sc molecules seeding wild-type brain homogenate sPMCA reactions. In vitro-generated DC-PBD, DN-PBD, and DD-PBD
PrP
Sc molecules were propagated by sPMCA for three rounds with wild-type mouse brain homogenate, containing wild-type PrP
C substrate. Control
reactions seeded with wild-type native RML prions and unseeded reactions were also tested. One sample of each reaction was not subjected to
protease digestion (2PK), while all others were digested with 25 mg/mL proteinase K. PrP was detected by immunoblot (anti-PrP 6D11).
doi:10.1371/journal.ppat.1002128.g004
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Sc product. Thus, DC-PrP
Sc did not arise de
novo [11], but may have emerged from amplification of a few
molecules of a minority conformation present in the original PrP
Sc
seed. Such an event is consistent with recent reports of multiple
prion strains emerging from a single ‘‘pure’’ source [37,38], and 4–5
serial amplification rounds are required to detect PrP
Sc conformers
at very low concentrations [34].
Expanded substrate range and increased converting
efficiency of DC-PrP
Sc
Once formed, the novel DC-PrP
Sc molecules bound to and
propagated in DN-PrP
C and DD-PrP
C substrates, forming new
PrP
Sc molecules lacking either one or both polybasic domains.
Thus, in contrast to wild-type PrP
Sc, DC-PrP
Sc is universally
catalytic in polybasic mutant PrP
C, exhibiting an expanded
substrate range that points to an alternative docking mechanism
during propagation. Each of the DPBD PrP
Sc species propagated
robustly, including even the mutant lacking both polybasic
domains (DD). While wild-type PrP
Sc propagates by binding to
substrate polybasic domains, DPBD mutant PrP
Sc molecules
appear to utilize a different mechanism to bind PrP
C, as outlined
by the model in Figure 6. This indicates that prion docking, and
perhaps other events in conversion, do not necessarily follow a
rigidly conserved mechanism. In contrast, self-replicating fungal
prions appear to utilize a stereotypic mechanism requiring
glutamine/asparagine repeats [39].
The expanded interaction range of mutant PrP
Sc molecules could
be explained by the exposure of a neoepitope on mutant PrP
Sc
(Figure 6). If DPBD mutant PrP
Sc molecules propagate from a
minority constituent conformer within wild-type PrP
Sc, the putative
neoepitope may also be present on these minority seed molecules.
Mechanisms of PrP
Sc docking may also vary between different
natural prion strains. Further studies are required to assess binding-
site heterogeneity of PrP
Sc-PrP
C interactions, including identifica-
tion of specific docking sites used by DD-PBD molecules.
We also observed that DC-PrP
Sc molecules, once formed,
catalyzed nearly complete conversion of autologous substrate, ,5-
fold greater than wild-type PrP
Sc autocatalysis. Thus, DC-PrP
Sc
molecules show robust catalytic activity in terms of both substrate
range and prion protein converting efficiency.
Polybasic deficient PrP
Sc molecules resemble wild-type
PrP
Sc in vitro
Our biochemical analysis revealed that DPBD PrP
Sc mutants
possess all of the biochemical hallmarks that characterize wild-type
infectious prions. All three DPBD PrP
Sc mutants (DC, DN, and
DD) drive conversion of PrP
C in wild-type brain homogenate
sPMCA experiments, a model of the conversion event in prion
Table 1. Biological infectivity assay of in vitro-generated autocatalytic PrP
Sc molecules.
Incubation period (days)
Inoculum Catalytic PrP
Sc Dilution
dScrapie killed
eKilled, not scrapie
fUnspecified death
Wild-type PrP
Sc + 10
21 162,162,193,203
DC-PBD PrP
Sc + 10
21 453,460,469 371 350,418
10
22 461,547 317,397
10
23 611 398 388,507
10
24 547 275,505
10
25 245,421,448,587
10
26 426,635,635
10
27 635,635,635 427
a DN-PBD PrP
Sc + 10
21 564 455 360,394,405,421,480,511
a DD-PBD PrP
Sc + 10
21 457,477 239,294,347,450,466,490
10
22 393 371,541,576
10
23 233,478 464,595
10
24 581 456,556
10
25 602,602 428,498
10
26 337,366,548 450
10
27 602,602 490,590
b No PrP 2 10
21 427,635 576
c DC-PBD PrP
C 2 10
21 635,635 476
c DN-PBD PrP
C 2 10
21 602,602,602,602
c DD-PBD PrP
C 2 10
21 602,602,602 498,543,548
RML prions were propagated in vitro by sPMCA with purified CHO-expressed PrP
C+Prnp
0/0 brain homogenate.
aGenerated by in vitro propagation of DC-PBD PrP
Sc (Figure 2).
bPropagation in mock-purified untransfected CHO lysate+Prnp
0/0 brain homogenate.
cUnseeded PMCA reactions.
dUpon observation of clinical signs, scrapie illness was confirmed by Western blot for protease-resistant PrP and histopathology for spongiform degeneration.
eThese animals showed no clinical signs of scrapie illness, and upon death or sacrifice were found to be negative biochemically for protease-resistant PrP and
pathologically for spongiform degeneration. After .600 days post-inoculation, all remaining animals were sacrificed, analyzed for PrP
Sc, and included in this table.
fThese animals showed no clinical signs of scrapie illness, but tissue was not obtained due to sacrifice for other condition (such as dermatitis) or sudden death.
doi:10.1371/journal.ppat.1002128.t001
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Sc molecules are
resistant to stringent protease digestion, demonstrating a post-
digestion molecular weight shift that is characteristic of PrP
Sc.
DPBD PrP
Sc molecules are also autocatalytic, propagating
indefinitely in autologous PrP
C substrate. The propagation of
DPBD PrP
Sc requires an accessory cofactor provided by Prnp
0/0
brain homogenate. Thus, unlike some fungal protein conforma-
tions, which have been shown to propagate in vitro with only the
alternatively folded substrate protein [40,41,42,43], DPBD PrP
Sc
behaves like infectious mammalian prions in requiring a
supplementary cofactor for propagation [11,12,31,44,45].
Dissociation of brain homogenate sPMCA seeding
activity from in vivo infectivity
PrP
Sc table-1-captionmolecules generated from CHO-expressed
wild-type PrP
C induced scrapie illness in wild-type mice with a
Figure 5. Biochemical and neuropathological analysis of mice inoculated with in vitro-generated PrP
Sc molecules. Brains were
dissected from wild-type mice showing terminal scrapie signs (PrP
Sc and DC-PBD PrP
Sc inocula) or similarly aged mice not displaying scrapie signs
(mock-propagated, DN-PBD PrP
Sc, and DD-PBD PrP
Sc inocula). (A) Equivalent amounts of 10% brain homogenate were treated with buffer (2PK) or
25 mg/mL proteinase K (+PK to show PrP
Sc) and detected by anti-PrP (6D11) immunoblot. A greater exposure of the same immunoblot is displayed
below, to illustrate samples containing low amounts of PrP
Sc.( B) Neuropathology of cerebellum and hippocampus. Brain sections were stained with
hematoxylin and eosin (H&E). The black bar denotes 100 mm.
doi:10.1371/journal.ppat.1002128.g005
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contrast, despite exhibiting the in vitro hallmarks of wild-type
infectious PrP
Sc as described above, mutant DC-PrP
Sc and DN-
PrP
Sc molecules showed low infectivity in vivo (#3000 LD50 units/
mL and ,300 LD50 units/mL, respectively), and DD-PrP
Sc
showed no infectivity. Some inoculum-host PrP sequence N-
terminal differences can mildly prolong scrapie incubation time,
but these did not alter attack rates [46,47], and much larger N-
terminal PrP
Sc deletions than the DN-PrP
Sc that we report here
did not significantly affect incubation time or attack rate in wild-
type animals [23]. For example, protease-digested PrP
Sc yields
PrP27-30, which is highly infectious to wild-type animals despite
lacking amino acids 23–88 [48,49]. Given that DPBD PrP
Sc
molecules drive robust propagation in vitro in wild-type brain
homogenate sPMCA, their diminished biological infectivity was
highly unexpected, and represents dissociation between in vitro
catalysis and in vivo infectivity, most notably for DN-PBD and DD-
PBD PrP
Sc.
To our knowledge, this report is the first demonstration of
absent or minimal infectivity in samples that successfully seed
propagation of wild-type brain homogenate during sPMCA,
suggesting that the normal route of PrP
C/PrP
Sc interaction
through polybasic domains may be required for generating
infectious prions. Why might appropriate PBD-mediated interac-
tion be required for infectivity? One possibility is that PBD-
deficient PrP
Sc molecules may be more susceptible to existing host
mechanisms for prion clearance [50,51,52,53], perhaps by
exposure of a neoepitope on PrP
Sc that serves as a clearance
signal. If this explanation were correct, then all three PBD-
deficient PrP
Sc molecules must be preferential targets for the
clearance mechanism.
A more plausible explanation is that the non-PBD mediated
interaction mechanisms used by DPBD-PrP
Sc molecules to
propagate in vitro lead to the production of alternative PrP
Sc
conformations that are intrinsically non-infectious or have reduced
infectivity. Consistent with this explanation, we observed different
PrP
Sc glycosylation patterns in animals inoculated with DC-PrP
Sc
compared to animals inoculated with wild-type PrP
Sc. Such a
distinction could be caused by an altered ability of mutant PrP
Sc to
interact with non-PrP host molecules during in vivo propagation.
For example, the in vitro detergent micelle environment differs
from the membrane environments where propagation occurs in
vivo. On the other hand, high titers of strain-preserved prion
infectivity are propagated in vitro in detergent micelles [8,11,32],
suggesting that in vitro propagation recapitulates native events fairly
well.
Finally, it should be emphasized that although mutant PrP
Sc
molecules were used in this study to uncover the dissociation
between seeding ability and infectivity, the results are directly
relevant to the mechanisms responsible for forming naturally
occurring prions because normal wild type brain homogenates and
normal wild type mice were used in sPMCA seeding assays and in
vivo bioassays, respectively. The contrast between highly infectious
wild type PrP
Sc and minimally infectious DPBD-PrP
Sc molecules
provides a novel paradigm that can be used to determine the
specific structural basis of prion infectivity.
Figure 6. Model of PrP replicative interaction mechanisms. This diagram summarizes a proposed model for the interaction, propagation,
and infectivity behavior of wild-type and polybasic deletion mutant PrP molecules. Wild-type PrP
Sc seed binds and propagates efficiently with
autologous PrP
C substrate, using PrP
C polybasic domains (represented by rectangular protrusion) for docking. However, if PrP
C lacks one or
both polybasic domains, PrP
Sc binds less well and exhibits impaired propagation. If PrP
Sc molecules lacking polybasic domains can be formed,
they can bind and propagate efficiently with an expanded range of PrP
C substrates. DPBD-PrP
Sc may propagate by a different mechanism
than wild-type PrP
Sc, utilizing different residues (symbolized by round protrusion) of PrP
C for binding. A neoepitope (round depression) may
be exposed in the polybasic mutant PrP
Sc molecules. Legend: Sc=PrP
Sc;C = P r P
C;W T = w i l d - t y p e .DPBD=deletion in polybasic domain;
++=polybasicdomain.
doi:10.1371/journal.ppat.1002128.g006
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